vancouver british columbia, November 17, 2023 /CNW/- Asep Medical Holdings Inc. (“Asep Inc.”) or “company”) (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that it has entered into the final stages of approval of the draft registration statement on Form F-1 it has filed with the U.S. Securities and Exchange Commission (its plans to list on Nasdaq Stock exchanges list and trade common stocks.
This document was originally filed by Asep Inc. New York– Legal Counsel Sichenzia Ross Ference LLP, Friday, June 28, 2023.As previously announced, Asep Inc. also signed an agreement with a leading company New YorkUS-based investment bank Aegis Capital Corporation is involved in the listing process. The size and price range of the proposed listing have not yet been determined. The listing is subject to market and other conditions and completion of the SEC review process.
About ASEP Medical Holdings Limited
Asep Medical Holdings (asepmedical.com) is dedicated to solving the global problem of antibiotic failure by developing novel solutions to address significant unmet medical needs in human medicine. The company was formed from the merger of three existing private companies, all with advanced development technologies – Sepset Biosciences Inc., a proprietary diagnostic tool that enables early and timely identification of sepsis, ABT Innovations Inc., which solves multiple broad-spectrum treatment of these problems). -drug-resistant biofilm infections) and SafeCoat Medical Inc. (antimicrobial peptide medical device coating technology).
sepset biosciences inc.. (sepset.ca) is in the final stages of clinical research and preparation for commercialization of an in vitro diagnostic test that involves patient gene expression signatures to help assess the development of severe sepsis, one of the most important diseases that render antibiotics ineffective since the advent of antibiotics. One is the main initial treatment for sepsis. Sepsis was responsible for nearly 20% of deaths worldwide in 2017, and essentially all deaths were caused by COVID-19 and other epidemics.sepsetemergency room The test is a blood-based gene expression assay that is simple to administer, with results available in about an hour after a blood sample is collected in an emergency room or intensive care unit. This proprietary diagnostic technology, unlike current diagnostic tests, is able to assess the risk of progression to severe sepsis within approximately 60 minutes of starting the test. Bacterial culture is the gold standard and provides results after approximately 15 hours, but can take up to 3 hours. Asep believes its test will enable physicians to make critical early decisions about appropriate treatment, thereby reducing overall morbidity and mortality caused by sepsis.
ABT Innovation Company (abtinnovations.ca) Peptide technology covers a wide range of therapeutic applications, including bacterial biofilm infections (dental, wound, sinusitis, skin, medical device infections, chronic infections, lung, bladder, ENT, orthopedic, etc.), anti-inflammatory agents, Anti-infectious immunomodulators and vaccine adjuvants. The company’s first three indications are in preclinical development and the data are promising.
SafeCoat Medical Inc. (safecoatmedical.com) The technology involves self-assembling polymers combined with conjugated antimicrobial peptides that can be applied to a variety of surfaces as antimicrobial and antifouling coatings. Specifically, the present invention relates to coatings that can be applied to a variety of medical devices and implants and have demonstrated feasibility in animal models. The company’s expertise also includes methods for manufacturing and applying these antimicrobial coatings.
About Nasdaq
For more information about the Nasdaq Stock Exchange, please visit the Nasdaq website at www.nasdaq.com.
About Aegis Capital
Aegis Capital, Inc. (“Aegis”) has been engaged in wealth management and investment banking since 1984. Aegis provides corporate finance, strategic advisory and related services to public and private companies across multiple industries and geographies. Aegis also provides research, sales and trading services to institutional investors. Aegis provides its investment representatives with a conflict-free service platform that provides a full range of products and services, including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternative investments, equity research, fixed income and special purpose vehicles. aegiscapcorp.com
Forward-Looking Statements—
This press release contains certain “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements are often characterized by words such as “anticipate,” “plan,” “continue,” “expect,” “project,” “intend,” “believe,” “anticipate,” “estimate,” “may” and other similar words. The words “will,” “potential,” “proposal,” “positioning” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements include, but are not limited to, successful clinical testing of our sepsis in vitro diagnostic test and its proposed application for regulatory market authorization; that the company has not obtained regulatory market authorization as planned or at all; that it is conducting preclinical studies of our therapeutic lead and is expected to do so; This will result in rapid clinical trials; a timeline for identifying sepsis using the Company’s products; potential opportunities for revenue generation; the therapeutic efficacy of the Company’s products; and other statements regarding the Company’s proposed business plans. The forward-looking statements in this press release use various assumptions to draw conclusions or make predictions.Forward-looking statements are based on the opinions and estimates of management as of the date the statements are made and are subject to various risks, including the risk that the Company’s products may not perform as expected; the Company may not obtain necessary regulatory market authorizations or test results; the Company’s products Testing may be unsuccessful and market authorization may not be obtained within the timeframe anticipated or at all; the Company may not be able to generate revenue from its products as anticipated or at all; the markets for the Company’s products may differ from those described in this release; and Various other risk factors identified in Asep Medical Inc.’s prospectus dated November 9, 2021and the Company’s management’s discussion and analysis, which can be reviewed in the Company’s profile at www.sedar.com, uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Asep Medical Inc. disclaims any obligation to update or revise any forward-looking statements, and expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law Require.
View original content to download multimedia: https://www.prnewswire.com/news-releases/asep-inc-in-final-stage-of-approval-process-for-nasdaq-listing-registration-statement-301992570.html
SOURCE ASEP Healthcare Holdings, Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2023/17/c9451.html